导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -13.98% | 4030/4773 |
| 近一周 | -1.58% | 2899/5467 |
| 近一月 | -5.23% | 2252/5421 |
| 近一季 | -0.10% | 997/5238 |
| 近半年 | -15.29% | 4145/4931 |
| 近一年 | -20.24% | 3943/4400 |
| 近两年 | 46.83% | 1585/2954 |
| 近三年 | 9.80% | 1747/2253 |
| 成立以来 | -19.74% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-1.98% 2602/4961 |
-10.65% 4146/5312 |
- - |
- - |
| 2025 | 30.08% 1351/4813 |
2.36% 1397/3635 |
11.73% 138/4076 |
20.61% 1952/4524 |
-5.70% 3603/4813 |
| 2024 | 2.18% 1983/3463 |
-4.70% 1746/2808 |
-14.56% 2669/3014 |
21.41% 586/3129 |
3.36% 835/3463 |
| 2023 | 16.58% 29/2656 |
34.36% 58/2280 |
11.64% 14/2385 |
-18.72% 2348/2515 |
-4.39% 999/2655 |
| 2022 | -30.42% 1630/2207 |
-19.53% 1468/1919 |
-4.97% 1860/2016 |
-16.91% 1522/2113 |
9.52% 214/2208 |
| 2021 | 10.26% 436/1822 |
-4.92% 895/1255 |
7.44% 683/1330 |
-8.43% 1132/1466 |
17.87% 39/1822 |
| 2020 | 4.26% 908/1250 |
3.76% 108/1022 |
16.08% 455/1060 |
-1.22% 1054/1152 |
- - |
| 2019 | 58.48% 59/1092 |
30.74% 228/748 |
-9.66% 675/797 |
17.02% 11/844 |
14.66% 18/912 |
| 2018 | -30.00% 462/834 |
- - |
- - |
- - |
-8.20% 81/691 |
| 2017 | -26.93% 588/714 |
- - |
- - |
- - |
- - |
| 2016 | -25.95% 485/605 |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 港股医疗ETF | 1.4546 | 31.90% |
| 华富中证港股通创新药指数型发起式A | 1.1637 | 30.96% |
| 天弘恒生沪深港创新药精选50ETF发起联接A | 1.3128 | 30.52% |
| 中欧中证港股通创新药指数发起A | 1.6103 | 30.52% |
| 嘉实中证港股通创新药指数发起式C | 0.8566 | 30.50% |
| 中欧中证港股通创新药指数发起C | 1.4583 | 30.44% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8927 | 30.26% |
| 景顺长城中证港股通创新药ETF联接C | 1.4696 | 29.97% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8736 | 29.94% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8719 | 29.88% |
| 富国中证体育产业指数(LOF)A VS. 长安沪深300非周期A(740101) |